Search company, investor...

Karyopharm Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap




About Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing small molecule modulators of nuclear transport. Karyopharm's selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor proteins in the nucleus, resulting in anti-cancer activity across multiple tumor types. In collaboration with many academic laboratories, SINEs targeting the major nuclear exporter XPO1 (also called CRM1) exert robust anti-cancer activity in diverse pre-clinical models of cancer. The lead SINE KPT-330 is in two Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being evaluated as an oral treatment for dogs with Non-Hodgkin's Lymphoma, one of the most common canine cancers. The Company is also testing SINEs in autoimmune, viral, and dermatological disorders. The company was founded in 2008 and is based in Newton Center, Massachusetts.

Headquarters Location

85 Wells Avenue 2/F

Newton Center, Massachusetts, 02459,

United States


Missing: Karyopharm Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Karyopharm Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Karyopharm Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Karyopharm Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Karyopharm Therapeutics Patents

Karyopharm Therapeutics has filed 41 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Human proteins
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Proteins, Clusters of differentiation, Autoimmune diseases, Human proteins


Application Date


Grant Date



Related Topics

Transcription factors, Proteins, Clusters of differentiation, Autoimmune diseases, Human proteins



Latest Karyopharm Therapeutics News

Eltrombopag and Romiplostim Therapies Emerging as Effective Second-Line Chronic Immune Thrombocytopenia Treatment | FMI Predicts Korea to Remain a Key Revenue Generation Market

Mar 1, 2023

| FMI Predicts Korea to Remain a Key Revenue Generation Market Future Market Insights in its latest report predicts Korea  Thrombocytopenia Treatment Market  to progress at around 3.5% to 4.0% CAGR between 2023 and 2033. Sales of thrombocytopenia medication in the global market are slated to rise at a CAGR of 5.2% throughout the forecast period (2023 to 2033). Introduction of new treatments and medications for thrombocytopenia in Korea has the potential to revolutionize the way this condition is managed. Currently, the most common form of treatment for thrombocytopenia is platelet transfusions, but this has certain drawbacks, including the risk of infection and other complications. With the introduction of new and efficient medications, such as eltrombopag, romiplostim, and avatrombopag, patients will be able to access treatments that offer few risks and great efficacy. Similarly, the availability of these medications makes it easy for physicians to provide an accurate diagnosis and start appropriate treatment early. Early diagnosis and treatment of thrombocytopenia are critical, as they can help to reduce long-term complications and improve patient outcomes. These new medications also provide a wide range of therapeutic options that are tailored to the needs of individual patients. Sample of Research Report: Development of novel cost-effective treatments is also expected to increase access to thrombocytopenia treatment in Korea. Patients with thrombocytopenia often have difficulty getting treatment due to lack of resources or cost barriers, but with the introduction of affordable medications, people will have access to the care they need. The government of Korea is providing financial support to its citizens to help them access the best treatment available. This is not only beneficial to patients but also provides an incentive for healthcare providers to use the most up-to-date treatments These initiatives are expected to play a significant role in driving the demand for advanced treatments for thrombocytopenia in Korea. By providing financial support and incentives, governments can ensure that patients have access to the most effective treatments available and that healthcare professionals are using the best technologies available. This, in turn, will drive demand for advanced treatments for thrombocytopenia and help improve patient outcomes. Overall, the introduction of safe and efficient medication will drive growth in the thrombocytopenia treatment market in Korea. With increased availability of treatments and improved outcomes, people will be able to access the care they need and lead healthy lives. Ask A Question: The global thrombocytopenia treatment market is anticipated to surpass US$ 6 billion in 2023. By 2033, a massive valuation of US$ 10 billion has been predicted by Future Market Insights for the global thrombocytopenia treatment market. Korea’s thrombocytopenia treatment market is anticipated to account for a significant valuation by the end of 2033. Introduction of safe, efficient, and affordable medication and increasing government support are likely to provide an impetus to Korea’s thrombocytopenia treatment market. “Development of safe, affordable, and efficient medication coupled with favorable government schemes will provide an opportunity for market expansion in Korea. Hence, key companies are engaging in research and development practices to increase their market presence.”– Says an FMI Analyst. Competition Landscape in the Thrombocytopenia Treatment Market In order to gain a significant market position, key companies are investing in research and development practices to develop novel methods and treatments. In addition, these companies are also joining hands with online pharmacies to make their products available globally. Novartis Korea, Karyopharm Therapeutics Inc, and InnnoCare are apex companies in Korea thrombocytopenia treatment market. Recent Developments: In December 2022, Karyopharm Therapeutics Inc., a promotional pharma business developing innovative cancer treatments, confirmed recently updated Phase 1 findings from its research investigating the safety and effectiveness of once-weekly selinexor in conjunction with standard dosage ruxolitinib in individuals with medicine myelofibrosis (NCT04562389). In May 2018, Revolade, manufactured by Novartis Korea, was officially approved to treat severe aplastic anemia in patients who have not responded well to immunosuppressive medication. As a result of the bone marrow’s inability to make enough blood cells for the body, people with severe aplastic anemia have symptoms including exhaustion, dyspnea, and unusual bleeding or bruises. Anticoagulant therapy  depends on the underlying cause of the condition. Some of the common treatments for thrombocytopenia include: Treating the underlying cause: If the thrombocytopenia is caused by an underlying medical condition such as a viral infection, treating the condition can help improve platelet count. Medications: In some cases, medications such as corticosteroids, immune globulin, or thrombopoietin receptor agonists may be prescribed to help increase platelet count. Platelet transfusion: If a person has a very low platelet count and is at risk of bleeding, a platelet transfusion may be necessary to help prevent bleeding. Surgery: If thrombocytopenia is caused by an enlarged spleen, surgery to remove the spleen may be recommended. Lifestyle modifications: Avoiding activities that increase the risk of bleeding, such as contact sports, can help reduce the risk of bleeding in people with thrombocytopenia. It is important to work with a healthcare professional to determine the best treatment plan for thrombocytopenia based on the individual’s specific circumstances.

Karyopharm Therapeutics Frequently Asked Questions (FAQ)

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Where is Karyopharm Therapeutics's headquarters?

    Karyopharm Therapeutics's headquarters is located at 85 Wells Avenue, Newton Center.

  • What is Karyopharm Therapeutics's latest funding round?

    Karyopharm Therapeutics's latest funding round is IPO.

  • How much did Karyopharm Therapeutics raise?

    Karyopharm Therapeutics raised a total of $100.2M.

  • Who are the investors of Karyopharm Therapeutics?

    Investors of Karyopharm Therapeutics include Delphi Ventures, New Leaf Venture Partners, Foresite Capital, Chione and Multiple Myeloma Research Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.